The company expects to recruit around 120 newly-diagnosed GBM patients at treatment centers in the US and India in order to evaluate Azixa combination therapy as a first-line GBM treatment.
Azixa, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.
The license agreement requires Myrexis to make milestone payments and pay license fees as well as a royalty to EpiCept on sales of EP90745-related products, assuming successful commercialization of any compound within the EP90745 series.